Moderna, Inc. (0A45.IL)
| Previous close | 119.40 |
| Open | 124.36 |
| Bid | 121.30 x N/A |
| Ask | 127.52 x N/A |
| Day's range | 122.12 - 126.40 |
| 52-week range | 62.55 - 142.32 |
| Volume | |
| Avg. volume | 18,428 |
| Market cap | 60.487B |
| Beta (5Y monthly) | 1.64 |
| PE ratio (TTM) | 46.42 |
| EPS (TTM) | 2.68 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Yahoo Finance Video
Novo Nordisk slides while Moderna pops: Tale of two pharma stocks
Pharmaceutical stocks Novo Nordisk (NVO) and Moderna (MRNA) are trending in opposite directions following their earnings reports. Despite topping Wall Street's profit expectations, Novo Nordisk shares are sinking as the company fell short of estimates for its popular GLP-1 weight-loss drug, Wegovy. Meanwhile, Moderna is on the rise even after reporting first quarter losses. Moderna's growth is largely due to an uptick in coronavirus boosters and an expansion into the Brazillian market. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl
Simply Wall St.Moderna First Quarter 2024 Earnings: Beats Expectations
Moderna ( NASDAQ:MRNA ) First Quarter 2024 Results Key Financial Results Revenue: US$167.0m (down 91% from 1Q 2023...
- GuruFocus.com
Moderna Inc (MRNA) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges with ...
Despite a significant revenue drop, Moderna showcases robust clinical progress and strategic collaborations.
